Biomarcadores de respuesta a la inmunoterapia y a otros tratamientos en la práctica clínica asistencial: Retos y perspectivas de futuro

6 / 43

Treating cancer types based on genomic profiles: targeted therapies
Ado-trastuzumab
emtansine (Kadcyla)
BREAST CANCER
Afatinib
(EGFR+)
LUNG CANCER
Gefitinib
(EGFR+)
LUNG CANCER
Erlotinib
(EGFR+)
LUNG CANCER
Osimertinib (Tagrisso)
(T790M+)
LUNG CANCER
Crizotinib
(ALK/ROS/MET+)
LUNG CANCER
Alectinib
(ALK+)
LUNG CANCER
Dabrafenib+Trametinib
(BRAF V600E+)
LUNG CANCER
Vemurafenib (Zelboraf)
(BRAF+)
MELANOMA
Cetuximab (Erbitux)
(KRAS wt)
CCR
Dabrafenib (Tafinlar)
(BRAF V600+)
MELANOMA
Lapatinib (Tykerb)
(HER2+)
BREAST CANCER
Neratinib (Nerlynx)
(HER2+)
BREAST CANCER
Olaparib (Lynparza)
(BRCA-1+)
OVARIAN
Palbociclib (Ibrance)
(HR+/HER2-)
BREAST CANCER
Panitumumab (Vectibix)
(KRAS wt)
CCR
Pertuzumab (Perjeta)
(HER2+)
BREAST CANCER
Rucaparib (Rubraca)
(BRCA-1+)
OVARIAN
Trametinib (Mekinist)
(BRAF V600+)
MELANOMA
Trastuzumab (Herceptin)
(HER2+)
BREAST CANCER
Trastuzumab (Herceptin)
(HER2+)
GASTRIC CANCER
Cobimetinib (Cotellic)
(BRAF V600E/K+)
MELANOMA
Imatinib (Gleevec)
KIT+
GIST
Ribociclib (Kisqali)
(HR+/HER2-)
BREAST CANCER